This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lang, N. N. Articles by Newby, D. E. Search for Related Content PubMed Articles by Lang, N. N. Articles by Newby, D. E. Related Collections Related Article

CLINICAL RESEARCH: VASCULAR MEDICINE

Marked Impairment of Protease-Activated Receptor Type 1-Mediated Vasodilation and Fibrinolysis in Cigarette Smokers

Smoking, Thrombin, and Vascular Responses In Vivo

Ninian N. Lang, MRCP^_*,_*, Ingibjörg J. Guðmundsdóttir, MRCP^_*, Nicholas A. Boon, MD, FRCP, Christopher A. Ludlam, PhD, FRCP^_*, Keith A. Fox, FRCP, FESC^_* and David E. Newby, PhD, FRCP^_*

^_* Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom
Department of Cardiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.

Manuscript received January 7, 2008; revised manuscript received March 25, 2008, accepted April 2, 2008.

^_* Reprint requests and correspondence: Dr. Ninian N. Lang, Centre for Cardiovascular Science, The University of Edinburgh, Chancellor's Building, Edinburgh, EH16 4SU, United Kingdom. (Email: ninian.lang{at}ed.ac.uk).

Objectives: We sought to test the hypothesis that cigarette smoking adversely alters protease-activated receptor type 1 (PAR-1)-mediated vascular effects in vivo in humans.

Background: Distinct from its role in the coagulation cascade, thrombin exerts its major cellular and cardiovascular actions via PAR-1. The activation of PAR-1 causes endothelium-dependent arterial vasodilation and the release of endogenous fibrinolytic factors.

Methods: Forearm blood flow was measured with venous occlusion plethysmography in 12 cigarette smokers and 12 age- and gender-matched nonsmokers during intrabrachial infusions of PAR-1–activating-peptide (SFLLRN; 5 to 50 nmol/min), bradykinin (100 to 1,000 pmol/min), and sodium nitroprusside (2 to 8 µg/min). Plasma tissue plasminogen activator (t-PA) and plasminogen-activator inhibitor 1 antigen and activity concentrations were measured throughout the experiment.

Results: All agonists caused dose-dependent increases in forearm blood flow (p < 0.0001 for all). Although bradykinin and sodium nitroprusside caused similar vasodilation, SFLLRN-induced vasodilation was attenuated in smokers (p = 0.04). Smokers had modest reductions in bradykinin-induced active t-PA release (reduced by 37%, p = 0.03) and had a marked impairment of SFLLRN-induced t-PA antigen (p = 0.02) and activity (p = 0.006) release, with a 96% reduction in overall net t-PA antigen release. The use of SFLLRN also caused similar (p = NS) increases in inactive plasminogen-activator inhibitor 1 in both smokers and nonsmokers (p 0.002 for both).

Conclusions: Cigarette smoking causes marked impairment of PAR-1–mediated endothelial vasomotor and fibrinolytic function. Relative arterial stasis and near abolition of t-PA release will strongly promote clot propagation and vessel occlusion. These findings suggest a major contribution of impaired endothelial PAR-1 action to the increased atherothrombotic risk of cigarette smokers.

Key Words: smoking • thrombosis • fibrinolysis • blood flow • endothelium

Abbreviations and Acronyms   ANOVA = analysis of variance   EDHF = endothelium derived hyperpolarizing factor   NO = nitric oxide   PAI-1 = plasminogen activator inhibitor type 1   PAR = protease-activated receptor   t-PA = tissue-type plasminogen activator   vWF = von Willebrand factor

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A32. [Full Text] [PDF]